US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Free naloxone nasal spray needed to deal with Sask. overdose spike, say front-line groups
In the midst of an overdose crisis, organizations are calling for the Saskatchewan government to fund naloxone nasal spray, ...
Stocktwits on MSN1d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive
Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
MPR1d
FDA Decision on Etripamil Nasal Spray Delayed Due to Nonclinical Issues
The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Fierce Pharma1d
Manufacturing issues trip up Milestone's long-awaited FDA landmark
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
The fate of addiction treatment hangs in the balance with Kennedy’s HHS overhaul
The proposed overhaul of the U.S. Department of Health and Human Services could weaken and possibly eliminate a little-known ...
FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray
The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Here’s what happens to the body if you use too much nasal spray
Nasal sprays are often the go-to remedy for relief from a blocked nose or persistent allergies. Their quick, targeted action ...
Multiple Sclerosis News Today1d
Foralumab Phase 2a trial starts dosing patients at Yale MS Center
A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...
Fierce Pharma9d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
US FDA declines to approve Milestone's heart rhythm nasal spray
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...